Cancers
Instructions for Authors
Submission Checklist
Please:
read the Aims & Scope to gain an overview and assess if your manuscript is suitable for this journal;
About Cancers
Aims
Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced.
There is, in addition, a unique feature of this journal: we accept studies showing meaningful but negative results. While there are many journals that focus on cancer studies, none of them actively accepts negative results. As a result, most negative data end up not being in the public domain even if the data were meaningfully negative and the study well designed. By accepting those negative results, our journal encourages scientists to share those data so that they would not need to repeat the experiments that somebody else has already done.
Scope
We publish high-quality articles including basic, translational, and clinical studies on all tumor types (https://medlineplus.gov/cancers.html).
use the Microsoft Word template or LaTeX template or Free Format Submission to prepare your manuscript;
make sure that issues about publication ethics, research ethics, copyright, authorship, figure formats, data and references format have been appropriately considered;
Ensure that all authors have approved the content of the submitted manuscript.
Authors are encouraged to add a biography (optional) to the submission and publish it.
Manuscript Submission Overview
Types of Publications
Cancers publishes the highest quality of Research Articles, Reviews, Perspectives and Editorials related to the care of patients with cancer such as clinical trials. Cancers adopts the WHO’s definition of Clinical Trial: “Any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes”. We only publish Clinical Trials that are already registered at Primary Registries recommended by the WHO. Prospective trial registration (registration before the clinical trial starts) is required for trials that started after ICMJE recommendations took effect on July 1, 2005. For those clinical trials that started before 1 July 2005, retrospective registration may be considered.
Manuscripts submitted to Cancers should neither be published previously nor be under consideration for publication in another journal. The main article types are as follows:
Articles: Original research manuscripts. The journal considers all original research manuscripts, provided that the work reports scientifically sound experiments and provides a substantial amount of new information, e.g., research articles using only one cell line for the experiments will not be considered for publication (experiments need to be repeated on 1-2 more cell lines); authors should consider in vivo studies using orthotopic or transgenic models to validate gene function; for all Western blot figures, densitometry readings/intensity ratio of each band should be included; the whole Western blot showing all bands and molecular weight markers should be included in the Supplementary Materials; gene silencing experiments should use at least two gene-specific siRNAs, etc.
Authors should not unnecessarily divide their work into several related manuscripts, although short Communications of preliminary, but significant, results will be considered. Quality and impact of the study will be considered during peer review.
Full experimental details must be provided so that the results can be reproduced. Cancers requires that authors publish all experimental controls and make full datasets available where possible (see the guidelines on Supplementary Materials and references to unpublished data).
Articles should have a main text of around 3000 words at minimum and should have more than 30 references. Cancers has no restrictions on the maximum length of research manuscripts, provided that the text is concise and comprehensive.
Reviews: These provide concise and precise updates on the latest progress made in a given area of research. Systematic reviews should follow the PRISMA guidelines. Review articles should be comprehensive and submitted by authors who are in the field. The main text of review papers should be around 4000 words at minimum and include at least two figures or tables.
……
更多详情：
https://www.mdpi.com/journal/cancers/instructions
